Strumento inattivo

Azioni Relypsa Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Relypsa : Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics	13/02/17
Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016	03/11/16
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia	30/08/16
Relypsa : Acquisition May Not Be in the Best Interests of RLYP Shareholders	25/07/16
RELYPSA, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Galenica May Be Unfair to Shareholders	22/07/16

Dirigenti	Titolo	Età	Da
David Bushinsky PRN	Corporate Officer/Principal	-	-
Gregory Oakes PRN	Corporate Officer/Principal	56	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd